{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:39:47Z","timestamp":1792661987215,"version":"4.5.0"},"reference-count":43,"publisher":"American Chemical Society (ACS)","issue":"2","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI082577"],"award-info":[{"award-number":["R01AI082577"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI114685"],"award-info":[{"award-number":["R01AI114685"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI124046"],"award-info":[{"award-number":["R01AI124046"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI126296"],"award-info":[{"award-number":["R21AI126296"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI127594"],"award-info":[{"award-number":["R21AI127594"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R56AI099476"],"award-info":[{"award-number":["R56AI099476"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1171488"],"award-info":[{"award-number":["OPP1171488"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["RD16\/0027\/0014"],"award-info":[{"award-number":["RD16\/0027\/0014"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["RD16\/0027\/0019"],"award-info":[{"award-number":["RD16\/0027\/0019"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["SAF2015-71444-P"],"award-info":[{"award-number":["SAF2015-71444-P"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["SAF2016-79957-R"],"award-info":[{"award-number":["SAF2016-79957-R"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>From a high-throughput screen of 42\u202f444 known human kinases inhibitors, a pyrazolo[1,5-b]pyridazine scaffold was identified to begin optimization for the treatment of human African trypanosomiasis. Previously reported data for analogous compounds against human kinases GSK-3\u03b2, CDK-2, and CDK-4 were leveraged to try to improve the selectivity of the series, resulting in 23a which showed selectivity for T. b. brucei over these three human enzymes. In parallel, properties known to influence the absorption, distribution, metabolism, and excretion (ADME) profile of the series were optimized resulting in 20g being progressed into an efficacy study in mice. Though 20g showed toxicity in mice, it also demonstrated CNS penetration in a PK study and significant reduction of parasitemia in four out of the six mice.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.9b01741","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T17:58:36Z","timestamp":1576605516000},"page":"756-783","source":"Crossref","is-referenced-by-count":18,"title":["Selectivity and\nPhysicochemical Optimization of Repurposed\nPyrazolo[1,5-\n                    <i>b<\/i>\n                    ]pyridazines for the Treatment\nof Human African Trypanosomiasis"],"prefix":"10.1021","volume":"63","author":[{"given":"Westley F.","family":"Tear","sequence":"first","affiliation":[{"name":"Northeastern University , , 360 Huntington Avenue , , ,","place":["Boston, Massachusetts, United States, 02115"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Bag","sequence":"additional","affiliation":[{"name":"Northeastern University , , 360 Huntington Avenue , , ,","place":["Boston, Massachusetts, United States, 02115"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Diaz-Gonzalez","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Ceballos-Pe\u0301rez","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo I.","family":"Rojas-Barros","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cordon-Obras","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiomar","family":"Pe\u0301rez-Moreno","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Garci\u0301a-Herna\u0301ndez","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Santos","family":"Martinez-Martinez","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , , ,","place":["Tres Cantos, Spain, 28760"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Ruiz-Perez","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gamarro","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Gonzalez Pacanowska","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor R.","family":"Caffrey","sequence":"additional","affiliation":[{"name":"University of California San Diego , , 9500 Gilman Drive , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8992-0919","authenticated-orcid":true,"given":"Lori","family":"Ferrins","sequence":"additional","affiliation":[{"name":"Northeastern University , , 360 Huntington Avenue , , ,","place":["Boston, Massachusetts, United States, 02115"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Manzano","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline , , ,","place":["Tres Cantos, Spain, 28760"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Navarro","sequence":"additional","affiliation":[{"name":"Instituto de Parasitologi\u0301a y Biomedicina \u201cLo\u0301pez-Neyra\u201d, Consejo Superior de Investigaciones Cientificas (CSIC) , ,","place":["Granada, Spain, 18016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-7197","authenticated-orcid":true,"given":"Michael P.","family":"Pollastri","sequence":"additional","affiliation":[{"name":"Northeastern University , , 360 Huntington Avenue , , ,","place":["Boston, Massachusetts, United States, 02115"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"2026090218242011200_cit1","unstructured":"About Sleeping\nSickness. https:\/\/www.dndi.org\/diseases-projects\/hat\/ (accessed Jan 25, 2018)."},{"key":"2026090218242011200_cit2","unstructured":"Trypanosomiasis,\nhuman African (sleeping sickness). http:\/\/www.who.int\/mediacentre\/factsheets\/fs259\/en\/ (accessed Jan 25, 2018)."},{"issue":"3","key":"2026090218242011200_cit3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.pt.2017.12.002","article-title":"Fexinidazole:\nA New Drug for African Sleeping Sickness on the Horizon","volume":"34","author":"Pollastri","year":"2018","journal-title":"Trends Parasitol."},{"issue":"9709","key":"2026090218242011200_cit4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"2026090218242011200_cit5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/sj.bjp.0707354","article-title":"Human African trypanosomiasis:\npharmacological re-engagement with a neglected disease","volume":"152","author":"Barrett","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"2026090218242011200_cit6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/RRTM.S34399","article-title":"Monitoring the use\nof nifurtimox-eflornithine\ncombination therapy (NECT) in the treatment of second stage gambiense\nhuman African trypanosomiasis","volume":"3","author":"Franco","year":"2012","journal-title":"Res. Rep. Trop.\nMed."},{"issue":"11","key":"2026090218242011200_cit7","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1086\/522982","article-title":"Nifurtimox-eflornithine\ncombination therapy for second-stage Trypanosoma brucei gambiense\nsleeping sickness: a randomized clinical trial in Congo","volume":"45","author":"Priotto","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"9683","key":"2026090218242011200_cit8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination\ntherapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis:\na multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"2026090218242011200_cit9","article-title":"Phase II\/III studies show high efficacy and\nsafety of fexinidazole,\nthe first oral treatment for sleeping sickness","year":"2017"},{"issue":"10116","key":"2026090218242011200_cit10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma\nbrucei gambiense trypanosomiasis: a pivotal multicentre, randomised,\nnon-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"key":"2026090218242011200_cit11","unstructured":"European\nMedicines Agency recommends fexinidazole, the first all-oral treatment\nfor sleeping sickness. https:\/\/www.dndi.org\/2018\/media-centre\/press-releases\/ema-recommends-fexinidazole-first-all-oral-treatment-sleeping-sickness\/ (accessed Dec 5, 2018)."},{"issue":"7","key":"2026090218242011200_cit12","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1128\/AAC.00332-10","article-title":"Cross-resistance to nitro drugs and implications for\ntreatment of human African trypanosomiasis","volume":"54","author":"Sokolova","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"2026090218242011200_cit13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the\ntreatment of trypanosomatid diseases:\npast, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends\nParasitol."},{"key":"2026090218242011200_cit14","unstructured":"Pivotal\nclinical trial to begin for first oral drug candidate specifically\ndeveloped for sleeping sickness. https:\/\/www.dndi.org\/2015\/media-centre\/press-releases\/pr-scyx-7158\/ (accessed Jan 31, 2018)."},{"issue":"8","key":"2026090218242011200_cit15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000440","article-title":"Advancing drug innovation for neglected diseases-criteria\nfor lead progression","volume":"3","author":"Nwaka","year":"2009","journal-title":"PLoS Neglected Trop. Dis."},{"key":"2026090218242011200_cit16","unstructured":"Neglected\nTropical Diseases. http:\/\/www.who.int\/neglected_diseases\/diseases\/en\/ (accessed Jan 25, 2018)."},{"issue":"11","key":"2026090218242011200_cit17","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1016\/j.bmcl.2016.03.103","article-title":"Repurposing strategies for tropical\ndisease drug discovery","volume":"26","author":"Klug","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"2026090218242011200_cit18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003253","article-title":"Identification and characterization of hundreds of\npotent and selective inhibitors of Trypanosoma brucei growth from\na kinase-targeted library screening campaign","volume":"8","author":"Diaz","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"4","key":"2026090218242011200_cit19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001017","article-title":"Trypanosoma brucei\nglycogen synthase\nkinase-3, a target for anti-trypanosomal drug development: a public-private\npartnership to identify novel leads","volume":"5","author":"Oduor","year":"2011","journal-title":"PLoS Neglected\nTrop. Dis."},{"issue":"10","key":"2026090218242011200_cit20","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1128\/AAC.00364-08","article-title":"Glycogen\nsynthase kinase 3 is a potential drug target for African trypanosomiasis\ntherapy","volume":"52","author":"Ojo","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20132","key":"2026090218242011200_cit21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbapap.2005.08.018","article-title":"Protein kinases as drug targets in\ntrypanosomes and Leishmania","volume":"1754","author":"Naula","year":"2005","journal-title":"Biochim. Biophys.\nActa, Proteins Proteomics"},{"key":"2026090218242011200_cit22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1471-2164-6-127","article-title":"Comparative analysis\nof the kinomes of three pathogenic trypanosomatids: Leishmania major,\nTrypanosoma brucei and Trypanosoma cruzi","volume":"6","author":"Parsons","year":"2005","journal-title":"BMC\nGenomics"},{"issue":"6","key":"2026090218242011200_cit23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development\nof a central nervous system multiparameter optimization (CNS MPO)\napproach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"9","key":"2026090218242011200_cit24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046172","article-title":"Hit-to-lead\ndevelopment of the chamigrane endoperoxide merulin A for the treatment\nof African sleeping sickness","volume":"7","author":"Navarro","year":"2012","journal-title":"PLoS One"},{"key":"2026090218242011200_cit25","unstructured":"Target\nProduct Profile - Sleeping Sickness. https:\/\/www.dndi.org\/diseases-projects\/hat\/hat-target-product-profile\/ (accessed Jun 20, 2019)."},{"issue":"19","key":"2026090218242011200_cit26","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1021\/jm040063i","article-title":"N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines\nas Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with\nGood Cellular Efficacy","volume":"47","author":"Tavares","year":"2004","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026090218242011200_cit27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/protein\/gzi074","article-title":"Inhibitory mode of\nN-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series\nderivatives against GSK-3: molecular docking and 3D-QSAR analyses","volume":"19","author":"Xiao","year":"2006","journal-title":"Protein Eng., Des. Sel."},{"key":"2026090218242011200_cit28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1021\/acsinfecdis.8b00136","article-title":"GW779439X and Its Pyrazolopyridazine\nDerivatives Inhibit the Serine\/Threonine Kinase Stk1 and Act As Antibiotic\nAdjuvants against beta-Lactam-Resistant Staphylococcus aureus","volume":"4","author":"Schaenzer","year":"2018","journal-title":"ACS Infect. Dis."},{"issue":"18","key":"2026090218242011200_cit29","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1021\/jm500239b","article-title":"The design and synthesis of potent\nand selective inhibitors\nof Trypanosoma brucei glycogen synthase kinase 3 for the treatment\nof human african trypanosomiasis","volume":"57","author":"Urich","year":"2014","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026090218242011200_cit30","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/cmdc.201300072","article-title":"From on-target\nto off-target activity: identification\nand optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation\nas anti-Trypanosoma brucei drug discovery lead molecules","volume":"8","author":"Woodland","year":"2013","journal-title":"ChemMedChem"},{"issue":"21","key":"2026090218242011200_cit31","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1016\/j.bmcl.2008.09.069","article-title":"Synthesis and evaluation\nof pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase\ninhibitors","volume":"18","author":"Stevens","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"28","key":"2026090218242011200_cit32","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1016\/j.tetlet.2006.05.036","article-title":"Efficient Pd-catalyzed synthesis\nof 2-arylaminopyrimidines via microwave irradiation","volume":"47","author":"Zhang","year":"2006","journal-title":"Tetrahedron Lett."},{"key":"2026090218242011200_cit33","unstructured":"Hagan, J. J.; Ratti, E.; Routledge, C.\n          Use\nof Cyclooxygenase-2\nInhibitors for the Treatment of Depressive Disorders. Patent WO\/2005\/048999, 2005."},{"issue":"6","key":"2026090218242011200_cit34","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1021\/jm101356p","article-title":"Improvement in aqueous solubility in small molecule\ndrug discovery programs by disruption of molecular planarity and symmetry","volume":"54","author":"Ishikawa","year":"2011","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026090218242011200_cit35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/acs.jmedchem.8b01365","article-title":"Improvement of Aqueous\nSolubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine\nLead for Human African Trypanosomiasis Drug Development","volume":"62","author":"Bachovchin","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026090218242011200_cit36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1124\/jpet.105.090266","article-title":"Long-term\ntreatment with novel glycogen synthase kinase-3\ninhibitor improves glucose homeostasis in ob\/ob mice: molecular characterization\nin liver and muscle","volume":"316","author":"Kaidanovich-Beilin","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"2026090218242011200_cit37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003704","article-title":"Fitness of Leishmania\ndonovani parasites resistant to drug combinations","volume":"9","author":"Garcia-Hernandez","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"7","key":"2026090218242011200_cit38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005680","article-title":"Phenotypic, chemical and functional\ncharacterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as\na potential anthelmintic drug target","volume":"11","author":"Long","year":"2017","journal-title":"PLoS Neglected\nTrop. Dis."},{"issue":"180","key":"2026090218242011200_cit39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2019.00180","article-title":"Bioactivity\nof Farnesyltransferase Inhibitors Against Entamoeba histolytica and\nSchistosoma mansoni","volume":"9","author":"Probst","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"7","key":"2026090218242011200_cit40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000478","article-title":"Drug discovery\nfor schistosomiasis: hit and lead compounds identified in a library\nof known drugs by medium-throughput phenotypic screening","volume":"3","author":"Abdulla","year":"2009","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"7","key":"2026090218242011200_cit41","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1128\/AAC.02481-13","article-title":"4-Amino bis-pyridinium\nderivatives as novel antileishmanial\nagents","volume":"58","author":"Gomez-Perez","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20132","key":"2026090218242011200_cit42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijpharm.2008.05.001","article-title":"In vitro plasma stability, permeability and solubility of mercaptoacetamide\nhistone deacetylase inhibitors","volume":"361","author":"Konsoula","year":"2008","journal-title":"Int. J. Pharm."},{"key":"2026090218242011200_cit43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1021\/ci00063a006","article-title":"Atomic\nPhysiochemical\nParameters for Three Dimensional Structure Directed Structure-Activity\nRelationships. 4. Additional Parameters for Hydrophobic and Dispersive\nInteractions and Their Application for an Automated Superposition\nof Certain Naturally Occuring Nucleoside Antibiotics","volume":"29","author":"Viswanadhan","year":"1989","journal-title":"J. Chem. Inf. Model."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.9b01741","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/2\/756\/67035711\/acs.jmedchem.9b01741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/63\/2\/756\/67035711\/acs.jmedchem.9b01741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:24:30Z","timestamp":1788387870000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/63\/2\/756\/1305269\/Selectivity-and-Physicochemical-Optimization-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,12,17]]},"published-print":{"date-parts":[[2020,1,23]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01741","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]}}}